CHICAGO — Transrectal ultrasound-guided (TRUS) prostate biopsy poorly detects and rules out clinically significantprostate cancer, whereas multi-parametric magnetic resonance imaging (MP-MRI) can identify 27% of men who might safely avoid unnecessary biopsy, a study presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting showed.1
"The current diagnosis pathway can result in various errors: clinically indolent cancers are identified by chance; clinically significant lesions are missed; important cancers are incorrectly classified as unimportant; and men undergo whole-gland treatment, which carries harm," said co-investigator and presenter Hashim Ahmed, PhD, an MRC clinician scientist at University College London Hospitals in the United Kingdom.
Because MP-MRI as a triage test might allow men to avoid unnecessary TRUS-biopsy, since men with an elevated PSA do not have clinically significant prostate cancer, researchers evaluated the accuracy of MP-MRI followed by TRUS-biopsy vs template prostate mapping biopsy (TPM-biopsy) as an accurate reference test.
Intimacy during Prostate cancer treatment 
Nitric Oxide -- slows prostate cancer progression and PSA doubling time.
The association between serum lipid profile and the prostate cancer risk and aggressiveness
Hope for those with loss of PTEN in Prostate Cancer 
